BriaCell Therapeutics Corp (TSX:BCT)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - BCT

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - BCT

  • Market CapCAD82.870m
  • SymbolTSX:BCT
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINCA10778Y3023

Company Profile

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.BriaCell Therapeutics Corp is an immuno oncology biotechnologu company with a focus on cancer immunotherapy. It has developed a patented whole-cell cancer vaccine, called the 'BriaVax' vaccine.

Latest BCT news

Currently there for this company. Visit our news hub for other news .